Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Small interfering RNA Stories

2011-02-23 01:00:00

LONDON, Feb. 23, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office (USPTO). The issued patent, which represents a continuation of previously issued U.S. Patent Number 7,452,987, covers chemically modified RNAi molecules with defined positional modifications including siRNA molecules that are blunt ended, as well...

2011-01-13 14:29:53

Laboratory study indicates need for more clinical research of mechanisms that influence the activity of oxaliplatin Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics Research Institute (TGen). The drug, oxaliplatin, is widely used in colon cancer. It is used in early disease, following surgery in those cancers that are likely to recur. It is also...

2011-01-04 10:20:00

HAMILTON, N.J., Jan. 4, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County. VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They...

2011-01-04 06:15:00

HOERSHOLM, Denmark and SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc. (NYSE: PFE), today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform. Under the terms of the expanded...

2010-12-21 01:00:00

LONDON, Dec. 21, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases, today provides a year-end update on trading and the offer-period. Phil Haworth, CEO of Silence Therapeutics, comments: "2010 has been an exciting year for Silence Therapeutics. The Company is...

2010-12-10 14:36:39

Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers writing in BioMed Central's open access Journal of Translational Medicine carried out a series of in vitro tests which demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA (siRNA) can prevent it. Wei-Ping Min, from the University of Western Ontario, Canada, worked with a team of...

2010-12-02 07:45:00

GAITHERSBURG, Md., Dec. 2, 2010 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has cemented a partnership with a Chinese pharmaceutical company for development of its small interfering RNA (siRNA) therapeutic (STP705) for scarless wound healing. The partnership specifically covers the regulatory development and sale of STP705 in the Greater China market. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing...

2010-11-10 01:00:00

LONDON, Nov. 10, 2010 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases...

2010-11-02 12:39:49

A long-standing barrier to successful gene therapy in humans has been the lack of a non-toxic and effective tool or vector to carry the gene into the cell. Now a Baylor College of Medicine researcher and her colleagues think they may have a solution "“ at least in the quest for a way to silence cancer genes. Their invention consists of tiny wound-up circular bits of DNA that carry a short "hairpin" of RNA. The researchers from BCM and The Methodist Hospital Research Institute called...

2010-10-25 03:39:00

AMSTERDAM, October 25, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment...